“By extending my shareholdings, I want to support Scandion Oncology and our two founders, Professor Nils Brunner and Dr. Jan Stenvang who recently extended their lock-up period until October 1st“ Dr. Peter Høngaard Andersen explains, and he continues; “The current massive sale of shares has put our share price under pressure and I want to demonstrate my faith and confidence in our technology and the team behind Scandion Oncology which have met their milestones”.

Scandion Oncology are currently in its first phase 2 study with  colorectal cancer patients with acquired resistance toward cancer treatment. Data from the first cohort of the part 1 of the study is expected to be released during this month. Our next clinical study with pancreatic cancer patients is expected to be initiated in the fall of 2020.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on July 03, 2020.

Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.